20-F: Tianan Technology Group Reports Profitable 2024 Amid Business Model Shift

Tianan Technology Group achieves net income in 2024 following a strategic shift towards graphene production and health therapy, marking a significant turnaround from the previous year.

Summary

• Tianan Technology Group Ltd., a British Virgin Islands corporation, reports its financial results for the year ended December 31, 2024.
• The company transitioned its business model in the third quarter of 2022 to focus on graphene production and the health therapy industry.
• In 2024, the company expanded its business by establishing Henan Qige as a wholly-owned subsidiary in China to enter the healthcare service sector.
• The company achieved a net income of $454,590 for the year ended December 31, 2024, compared to a net loss of $250,009 for the year ended December 31, 2023.
• Gross profit was $838,424 for the fiscal year ended December 31, 2024, an increase of $771,743 compared to $66,681 for the fiscal year ended December 31, 2023.
• Revenues were $1,783,130 for the fiscal year ended December 31, 2024, an increase of $1,536,511 compared to $246,619 in the same period for the fiscal year ended December 31, 2023.
• Operating expenses increased to $382,864 for the fiscal year ended December 31, 2024, from $316,006 in the same period for the fiscal year ended December 31, 2023.
• The company identified material weaknesses in its internal control over financial reporting related to a lack of accounting staff with appropriate knowledge of U.S. GAAP and SEC reporting requirements.
• The company is taking remedial measures to address these weaknesses, including hiring qualified accounting personnel and implementing training programs.
• The company may need to raise additional capital to fund its operating expenses, pay its obligations, and grow its business in the future.

Sentiment

Score: 7

Explanation: The document presents a positive financial turnaround with increased revenue and profit, but concerns about internal controls and the need for future capital raises temper the overall sentiment.

Positives

• The company achieved a net income of $454,590 in 2024, a significant improvement from the $250,009 net loss in 2023.
• Gross profit surged to $838,424 in 2024, marking an increase of $771,743 compared to the previous year.
• Revenues increased substantially to $1,783,130 in 2024, up from $246,619 in 2023.
• The company is taking remedial measures to address weaknesses in internal control over financial reporting.

Negatives

• The company identified material weaknesses in its internal control over financial reporting related to a lack of accounting staff with appropriate knowledge of U.S. GAAP and SEC reporting requirements.
• The company may need to raise additional capital to fund its operating expenses, pay its obligations, and grow its business in the future.

Risks

• The company's operations are subject to political, economic, and legal risks in the PRC.
• The company is exposed to foreign currency exchange risk.
• The company identified material weaknesses in its internal control over financial reporting.
• The company may need to raise additional capital, and there is no guarantee it will be able to obtain funding on favorable terms.

Future Outlook

The company anticipates that its current liquidity is not sufficient to meet its obligations and may need to raise additional capital to fund operating expenses and grow the business.

Industry Context

The company's shift towards graphene production and health therapy aligns with the growing trend of an aging population and the increasing demand for healthcare services, particularly in China.

Comparison to Industry Standards

• The global graphene market is expected to reach about $51.835 billion by 2030, with a compound annual growth rate of 23.56%.
• Asia Pacific was the largest market with a revenue of $67.8 million in 2022 and is the fastest-growing region with a projected CAGR of 51.0% over the forecast period.
• China is expected to emerge as a prominent market for graphene with a CAGR of 60.9% over the forecast period in terms of volume.
• Key players in the graphene market include Haydale Graphene Industries PLC, Graphensic AB, and Directa Plus.

Related Party Transactions

• During the years ended December 31, 2024, and 2023, the Company received total loan proceeds of $644,366 and $130,943, respectively, from Mr. Heng Fei Yang, the Companys CEO.
• During the years ended December 31, 2024 and 2023, the Company recorded sales to Suzhou Aixi Health Technology Co., Ltd. of $587,144 and $0, respectively.
• During the years ended December 31, 2024 and 2023, the Company recorded sales to Shanghai Shengji Trade Co., Ltd. of $56,291 and $0, respectively.

Stakeholder Impact

• Shareholders will benefit from the improved financial performance and the company's growth strategy.
• Employees will benefit from the company's investment in human resource development.
• Customers will benefit from the company's dedication to sales of high quality products that are tailored to customers requirements and needs.

Next Steps

• The company intends to continue taking remedial measures to address weaknesses in internal control over financial reporting.
• The company intends to expand its sales and distribution network to penetrate new geographic markets.
• The company intends to closely track and study the development trend of domestic and international graphene based products and other technology research so it can maintain its technological standards to meet consumer needs.

Key Dates

Keywords

financial results, graphene, health therapy, net income, revenue, internal control, China